New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should Be Accessible and Covered Similar to Medicare

Key Takeaways

• 92% favor no‑copay blood CRC screening
• 93% adherence to Shield test in real world
• 77% would avoid delay with FDA‑approved blood test
• 71% feel anxiety before colonoscopy
• Medicare now covers Shield, expanding access

Summary

Guardant Health released a Harris Poll showing 92% of Americans aged 45+ support no‑copay coverage for blood‑based colorectal cancer (CRC) screening. The survey highlighted anxiety around colonoscopies and disgust for stool tests as major barriers, while 77% said a FDA‑approved blood test would reduce delays. Guardant’s Shield™ test, the first FDA‑cleared blood‑based CRC screen, achieved a 93% completion rate in its first 100,000 orders. Medicare, VA and TRICARE now reimburse Shield, positioning it for broader market adoption.

Pulse Analysis

The Harris Poll data underscores a seismic shift in patient preferences for colorectal cancer screening. With 92% of eligible adults demanding no‑copay blood tests, the traditional reliance on colonoscopy and stool‑based kits is being challenged by anxiety, procedural inconvenience, and aversion to sample collection. This sentiment aligns with the 2021 USPSTF recommendation lowering the screening age to 45, yet guidelines have yet to fully integrate blood‑based options, leaving a sizable portion of the population unscreened.

Guardant’s Shield™ test leverages methylation partitioning cell‑free DNA to detect CRC with a simple venipuncture, delivering a 93% adherence rate in real‑world use—far surpassing completion rates for colonoscopy and stool tests. The test’s FDA approval in 2024 and its inclusion in the National Comprehensive Cancer Network (NCCN) guidelines validate its clinical credibility. Early‑stage detection through Shield can boost five‑year survival to 91%, reinforcing the economic and health benefits of moving patients from invasive to minimally invasive screening pathways.

Payer acceptance is the next catalyst for scaling. Medicare, Veterans Affairs Community Care, and TRICARE now reimburse Shield, effectively removing cost barriers for millions of Americans. This coverage, combined with strong consumer demand, is likely to prompt private insurers to follow suit, reshaping the CRC screening market. Wider adoption could lower overall treatment costs by catching cancers earlier, improve population health metrics, and accelerate the integration of liquid biopsy technologies into routine preventive care.